Research from the University of Pittsburgh explains why metastatic uveal melanoma is resistant to conventional immunotherapies and how adoptive therapy, which involves growing a patient’s T cells outside the body before reinfusing them, can successfully treat this rare and aggressive cancer.
Zachary SteinhartMaxwell FoiseyDebolina GangulySean Yamada-HunterThe Parker Institute for Cancer Immunotherapy, a collaborative consortium of the world’s leading immuno-oncology experts, named its 2024 class of Early Career Researcher awardees.
